Direxion Daily TSLA Bull 2X Shares vs Zoetis Inc — how do they compare? Direxion Daily TSLA Bull 2X Shares trades at $10.4 (market cap $3.97B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 7.6× Direxion Daily TSLA Bull 2X Shares's market cap, and Zoetis Inc pays a 2.9% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily TSLA Bull 2X Shares for 15 Days and Zoetis Inc for 70 Days on average.
| TSLL | ZTS | |
|---|---|---|
Market Cap | $3.97B | $30.20B |
Volume | 38,458,237 | 6,175,327 |
Sector | Leveraged / Inverse | Health |
52-Week High | $23.03 | $147.53 |
52-Week Low | $6.74 | $69.09 |
Typical Hold Time | 15 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
TSLL, the Direxion Daily TSLA Bull 2X Shares ETF, trades at $10.01, down 1.38% on the day, with a neutral technical signal overall. Recent news highlights its sensitivity to Tesla's volatility, including an 11% rally tied to Cybercab hype (Benzinga, 2026-09-03). Key support and resistance levels cluster around $10, with the RSI_6 at 79.53 indicating potential overbought conditions. Financial ratios are not applicable as this is a leveraged ETF tracking Tesla's daily performance.
The outlook for TSLL is directly tied to Tesla's stock movements, offering amplified gains but heightened risk from daily rebalancing. Investment opportunity exists for short-term traders betting on Tesla's momentum, yet risks include decay from volatility and dependence on a single stock's performance. Caution is advised due to the product's complex nature and potential for significant losses even when Tesla rises modestly over time.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal despite mixed moving averages and oscillators. The company shows strong profitability with a 27.69% net income margin and 64.91% ROE, though recent quarterly earnings have been inconsistent. Analyst consensus is a $87.33 price target with no sell ratings. Recent news highlights near-term headwinds in U.S. companion animal sales but underscores long-term resilience and undervaluation.
ZTS presents a compelling value opportunity with a low P/E of 11.92 and robust margins, but faces risks from competitive pressures and volatile earnings. Upside potential exists if the company executes on international growth and maintains its industry-leading profitability, though investors should monitor Q3 2026 results for confirmation of recovery trends.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →